research GLP-1 Receptor Analogs: Evidence Linking to Effect on Metabolic and Reproductive Functions in Patients with PCOS and Obesity
GLP-1 receptor analogs may help improve metabolism and reproductive health in people with PCOS and obesity.
Search
for
Sort by
Research
30 / 390 results
research Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons
GLP-1 RAs help with diabetes and skin issues but can cause skin reactions and surgery challenges.
research Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review
GLP-1 receptor agonists may cause hair loss, but more research is needed.
research GLP-1 RAs and Skin Health: Exploring Dermatologic Side Effects and Therapeutic Interventions
GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.
research Effects of Glucagon-like Peptide-1 Receptor Agonists on Skin Homeostasis and Skin Aging Processes
GLP-1 RAs may help wound healing but can also cause faster facial aging and skin issues.
research Effects of GLP ‐1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review
GLP-1 receptor agonists may cause hair loss, but regrowth is rare.
research Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends
GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.
research Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review
GLP-1 agonists may help treat certain skin conditions.
research Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review
GLP-1 receptor agonists for weight loss may cause hair loss, especially in women.
research The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?
GLP-1 receptor agonists can both help and harm hair, so careful monitoring is needed.
research Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review
GLP-1 receptor agonists help women with PCOS lose weight and improve health, but more research is needed on long-term effects.
research “From evidence to practice” – Insights from the multidisciplinary team on the optimal integration of GLP ‐1 receptor agonists in obesity management services
GLP-1 receptor agonists help with weight loss but need to be combined with other treatments for best results.
research Metabolic syndrome – a new definition and management guidelines A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, “Club 30” Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons
The Polish medical societies have redefined metabolic syndrome and recommend lifestyle changes, certain medications, and possibly bariatric surgery for treatment. They also discuss managing related health conditions.
research Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome
Medications for PCOS don't seem to raise heart disease risk.
research Non-Hormonal Treatment Options for Regulation of Menstrual Cycle in Adolescents with PCOS
Medications for glucose metabolism and weight control, combined therapy options, and herbal medicines may help regulate menstrual cycle in adolescents with PCOS.
research Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study
GLP-1RA therapy may increase the risk of hair loss.
research Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
GLP-1RAs, like semaglutide and tirzepatide, may cause hair loss, so patients should be informed and monitored.
research The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms
GLP-1RAs may cause hair loss but could also help regrow hair in some cases.
research Exploring the Role of GLP ‐1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review
GLP-1 receptor agonists may help manage and prevent diabetic foot ulcers.
research The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
research current possible treatment approaches of Polycystic Ovary Syndrome (PCOS)
Different treatments for PCOS should be tailored to the individual, including lifestyle changes and various medications.
research Methylene blue protects hair follicle stem cells from oxidative and metabolic stress to enhance hair regeneration
Methylene blue helps hair growth by protecting hair stem cells from stress.
research Semaglutide and the Skin: An Overview of Current Evidence
Semaglutide may help some skin disorders but can also cause skin issues.
research Telogen Effluvium and Metabolic Stress in Modern Weight Loss Interventions: A Narrative Clinical Review
Hair loss from weight-loss treatments is usually temporary and reversible.
research The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
The effect of GLP-1 RAs on erectile function is unclear and needs more research.
research Dermatologic Implications of GLP-1 Receptor Agonist Medications: A Comprehensive Review
GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.
research Balancing metabolic optimization and reproductive safety in Polycystic Ovary Syndrome: a Bayesian-informed framework for GLP-1 receptor agonists
The document discusses the use of GLP-1 receptor agonists (GLP-1RAs) in managing Polycystic Ovary Syndrome (PCOS), focusing on their metabolic benefits rather than confirmed fertility enhancement. The narrative synthesis highlights the need for individualized treatment plans, emphasizing the distinction between metabolic optimization and reproductive outcomes. The study suggests GLP-1RAs should be used as short-term, preconception tools, with careful planning for drug discontinuation to avoid rebound effects. The authors call for future trials to standardize reproductive endpoints and capture periconception exposure to better assess the benefits and risks.
research Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review
GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.
research Dercum Disease: Exploratory Therapeutic Approaches in the Absence of Standardized Medical Treatment—A Single Center Case Series
Individualized treatments may help manage Dercum's disease symptoms.
research Role of Sodium–Glucose Cotransporter-2 Inhibitors in Managing Polycystic Ovary Syndrome: A Systematic Review
SGLT2 inhibitors may help manage PCOS symptoms effectively.